Markman Advisors LLC

Markman Advisors is a patent-consultancy located in New York focusing on both pharma and non-pharma sectors.
Media Enquiries: Email or DM

[Zachary Silbersher @silbersher]

Can Ascendis avoid an ITC ban of its TransCon CNP based on public interest grounds? $ASND $BMRN https://t.co/2nyuCl6Gsb

[Zachary Silbersher @silbersher]

Can Amicus Therapeutics stop entry of Aurobindo’s generic Galafold? $FOLD #Galafold https://t.co/Yz0pCLJfWP

[Zachary Silbersher @silbersher]

Will an upcoming Markman hearing reveal if Ascendis’ TransCon CNP infringes Biomarin’s patent? $ASND $BMRN https://t.co/xtkTWZ8aua

[Zachary Silbersher @silbersher]

Will Moderna prevail against Arbutus on its § 1498 defense? A review of its summary judgment argument. $ABUS $MRNA $ROIV https://t.co/U7A0kedk6Y

[Zachary Silbersher @silbersher]

Can Madrigal Pharmaceutical’s new patent protect Rezdiffra until 2044? Patent likely allowed based upon unexpected results. $MDGL #rezdiffra https://t.co/WrBaISMxOM

[Zachary Silbersher @silbersher]

Can Biomarin stop Ascendis from importing its competing TransCon CNP against Voxzogo? $BMRN #voxzogo $ASND https://t.co/M3nRheSnek

[Zachary Silbersher @silbersher]

Are Ohtuvayre’s patents strong enough to protect Merck’s acquisition of Verona Pharma? $MRK $VRNA https://t.co/6LKjvQhKSR

[Zachary Silbersher @silbersher]

I was quoted in IAM on the PTAB's recent discretionary denial decisions, including the iRhythm, Posco and Procomm decisions. https://t.co/5ofPw0X3HL

[Zachary Silbersher @silbersher]

How many patents does Tesla have for its robotaxis? $TSLA @tesla https://t.co/qlypTTgz9W

[Zachary Silbersher @silbersher]

Could prosecution laches threaten Big Pharma patent evergreening? $CORT https://t.co/nJxPMfcdtb

[Zachary Silbersher @silbersher]

Will the Supreme Court save lower-cost medications from inducement by skinny labels? $AMRN https://t.co/SwCFQSoCqd

[Zachary Silbersher @silbersher]

Does Arbutus’ patent suit against Moderna’s Covid vaccine have a testing problem? $ABUS $ROIV $MRNA https://t.co/uKFrE0l0Cf

[Zachary Silbersher @silbersher]

Arbutus v. Moderna: I attended 5/7 conference. Parties summarized SJ motions/defenses, discussed important testing dispute. Judge orders narrowing issues for trial. Case going to trial, even if SJ motions filed, but September trial date likely to be extended. $ABUS $ROIV $MRNA

[Zachary Silbersher @silbersher]

How long can Pfizer keep out generics for its tafamidis Vyndamax and Vyndaqel drugs? $PFE @MarkmanAdvisors https://t.co/dagD1CePVz

[Zachary Silbersher @silbersher]

Arcutis Biotherapeutics & Padagis stay patent suit for Zoryve 0.3% cream. If stay lifted, Padagis agrees 30-month stay extended by every day stay is in place. Parties to update court every 60 days. Padagis awaits correspondence from FDA ... $ARQT #zoryve

[Markman Advisors LLC @MarkmanAdvisors]

$ABUS $MRNA Judge Goldberg sets trial date for 9/29/25 and pre-trial motions conference for May 7. On the agenda will be discussion of proposed summary judgment motions as well as any challenges to expert testimony under Daubert. Lots to watch in coming months as trial looms...

[Zachary Silbersher @silbersher]

Will Merck’s subcutaneous Keytruda infringe Halozyme's patents? $MRK $HALO @KEYTRUDA https://t.co/r8UPCsWHTn

[Markman Advisors LLC @MarkmanAdvisors]

$HIMS $LLY $NVO Judge Pittman cancels 3/27 hearing after review of administrative record. Reverts back to expedited summary judgment briefing, with hearing set for 4/24. Court continues to push this case to final decision with dispatch.

[Markman Advisors LLC @MarkmanAdvisors]

$HIMS $LLY $NVO Judge Pittman sets hearing date on March 27 on joint motion by @US_FDA and OFA for entry of final judgment based on his denial of OFA's motion for preliminary injunction. Parties will submit excerpts from administrative record by 3/25.

[Zachary Silbersher @silbersher]

Are Arbutus’ patents indefinite? $ABUS $MRNA $PFE @MarkmanAdvisors https://t.co/TLn2HmnveZ

[Zachary Silbersher @silbersher]

Will Novo Nordisk and Eli Lilly use their patents to block compounders for GLP-1 agonists? $NVO $LLY #semaglutide #tirzepatide @MarkmanAdvisors https://t.co/H3OAGeXxbE